Investment Analysts’ Weekly Ratings Changes for Zimmer Biomet (ZBH)

Posted by Teresa Graham on Nov 13th, 2026

Zimmer Biomet (NYSE: ZBH) recently received a number of ratings updates from brokerages and research firms:

11/9/2026 – Zimmer Biomet had its price target raised by Barclays from $100.00 to $115.00. They now have an “equal weight” rating on the stock.
11/5/2026 – Zimmer Biomet was given a new $114.00 price target by Truist Financial.
11/5/2026 – Zimmer Biomet had its price target raised by UBS Group from $120.00 to $130.00. They now have a “buy” rating on the stock.
11/5/2026 – Zimmer Biomet had its price target raised by JPMorgan Chase & Co. from $117.00 to $120.00. They now have a “neutral” rating on the stock.
11/5/2026 – Zimmer Biomet had its price target raised by Citigroup from $99.00 to $117.00. They now have a “neutral” rating on the stock.
11/5/2026 – Zimmer Biomet had its price target raised by Royal Bank Of Canada from $110.00 to $125.00. They now have an “outperform” rating on the stock.
11/5/2026 – Zimmer Biomet had its price target raised by Sanford C. Bernstein from $93.00 to $107.00. They now have a “market perform” rating on the stock.
11/5/2026 – Zimmer Biomet had its price target raised by Wells Fargo & Company from $103.00 to $113.00. They now have an “equal weight” rating on the stock.
11/4/2026 – Zimmer Biomet was given a new $125.00 price target by Stifel Nicolaus.
11/4/2026 – Zimmer Biomet had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $120.00 price target on the stock.
10/31/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
10/22/2026 – Zimmer Biomet had its “buy” rating reaffirmed by Argus. They now have a $125.00 price target on the stock.
10/7/2026 – Zimmer Biomet was upgraded by Barclays to “hold”.
10/6/2026 – Zimmer Biomet is now covered by Barclays. They set an “equal weight” rating and a $100.00 price target on the stock.
10/5/2026 – Zimmer Biomet had its “neutral” rating reaffirmed by Citigroup.
9/28/2026 – Zimmer Biomet had its “market perform” rating reaffirmed by BMO Capital Markets.
9/14/2026 – Zimmer Biomet was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Zimmer Biomet Price Performance

NYSE:ZBH traded down $1.38 during trading hours on Friday, hitting $103.18. 2,517,489 shares of the stock traded hands, compared to its average volume of 2,261,748. The company has a market cap of $19.53 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 2.52 and a beta of 0.50. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $112.54. The stock has a 50 day moving average price of $95.76 and a 200 day moving average price of $92.57. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.49.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. During the same period in the prior year, the company posted $1.90 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.56 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.30%.

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.